HEADER APOPTOSIS/APOPTOSIS INHIBITOR 19-FEB-20 6VWC TITLE CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH TETRAHYDROISOQUINOLINE- TITLE 2 PYRIDINE BASED INHIBITORS COMPND MOL_ID: 1; COMPND 2 MOLECULE: BCL-2-LIKE PROTEIN 1; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: BCL2-L-1,APOPTOSIS REGULATOR BCL-X; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BCL2L1, BCL2L, BCLX; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS BCL-XL INHIBITOR, APOPTOSIS, STRUCTURE-BASED DRUG DESIGN, APOPTOSIS- KEYWDS 2 APOPTOSIS INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR R.A.JUDGE,A.S.JUDD REVDAT 3 11-OCT-23 6VWC 1 REMARK REVDAT 2 04-NOV-20 6VWC 1 JRNL REVDAT 1 21-OCT-20 6VWC 0 JRNL AUTH L.WANG,G.A.DOHERTY,A.S.JUDD,Z.F.TAO,T.M.HANSEN,R.R.FREY, JRNL AUTH 2 X.SONG,M.BRUNCKO,A.R.KUNZER,X.WANG,M.D.WENDT,J.A.FLYGARE, JRNL AUTH 3 N.D.CATRON,R.A.JUDGE,C.H.PARK,S.SHEKHAR,D.C.PHILLIPS, JRNL AUTH 4 P.NIMMER,M.L.SMITH,S.K.TAHIR,Y.XIAO,J.XUE,H.ZHANG,P.N.LE, JRNL AUTH 5 M.J.MITTEN,E.R.BOGHAERT,W.GAO,P.KOVAR,E.F.CHOO,D.DIAZ, JRNL AUTH 6 W.J.FAIRBROTHER,S.W.ELMORE,D.SAMPATH,J.D.LEVERSON,A.J.SOUERS JRNL TITL DISCOVERY OF A-1331852, A FIRST-IN-CLASS, POTENT, AND JRNL TITL 2 ORALLY-BIOAVAILABLE BCL-X L INHIBITOR. JRNL REF ACS MED.CHEM.LETT. V. 11 1829 2020 JRNL REFN ISSN 1948-5875 JRNL PMID 33062160 JRNL DOI 10.1021/ACSMEDCHEMLETT.9B00568 REMARK 2 REMARK 2 RESOLUTION. 1.60 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.60 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 47.29 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 94.1 REMARK 3 NUMBER OF REFLECTIONS : 41328 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.180 REMARK 3 R VALUE (WORKING SET) : 0.179 REMARK 3 FREE R VALUE : 0.200 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 2074 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.60 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.62 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 68.41 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : NULL REMARK 3 BIN R VALUE (WORKING + TEST SET) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2402 REMARK 3 BIN FREE R VALUE : 0.3365 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 42 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2218 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 86 REMARK 3 SOLVENT ATOMS : 306 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 21.43 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.39400 REMARK 3 B22 (A**2) : -0.10940 REMARK 3 B33 (A**2) : -0.28460 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.20500 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.200 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.089 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.084 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.085 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.082 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.955 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.932 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2366 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 3203 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 805 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 486 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2366 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 273 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2550 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 0.83 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.35 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 14.59 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6VWC COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 20-FEB-20. REMARK 100 THE DEPOSITION ID IS D_1000247017. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 09-DEC-10 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS3 S 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 41362 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.604 REMARK 200 RESOLUTION RANGE LOW (A) : 47.290 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.2 REMARK 200 DATA REDUNDANCY : 3.000 REMARK 200 R MERGE (I) : 0.04900 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 14.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.60 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.61 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.35800 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 4QVX REMARK 200 REMARK 200 REMARK: CRYSTALS GREW AS PLATES REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.21 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.29 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 30%(W/V) PEG 10,000, 0.1M TRIS HCL PH REMARK 280 8.5, VAPOR DIFFUSION, TEMPERATURE 290K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 47.29200 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 GLY A 76 REMARK 465 GLY A 77 REMARK 465 GLY A 78 REMARK 465 GLY A 79 REMARK 465 GLY A 80 REMARK 465 GLY A 81 REMARK 465 ASN A 197 REMARK 465 ASN A 198 REMARK 465 ALA A 199 REMARK 465 ALA A 200 REMARK 465 ALA A 201 REMARK 465 GLU A 202 REMARK 465 SER A 203 REMARK 465 ARG A 204 REMARK 465 LYS A 205 REMARK 465 GLY A 206 REMARK 465 GLN A 207 REMARK 465 GLU A 208 REMARK 465 ARG A 209 REMARK 465 LEU A 210 REMARK 465 GLU A 211 REMARK 465 HIS A 212 REMARK 465 HIS A 213 REMARK 465 HIS A 214 REMARK 465 HIS A 215 REMARK 465 HIS A 216 REMARK 465 HIS A 217 REMARK 465 MET B 1 REMARK 465 SER B 75 REMARK 465 GLY B 76 REMARK 465 GLY B 77 REMARK 465 GLY B 78 REMARK 465 GLY B 79 REMARK 465 GLY B 80 REMARK 465 ASN B 197 REMARK 465 ASN B 198 REMARK 465 ALA B 199 REMARK 465 ALA B 200 REMARK 465 ALA B 201 REMARK 465 GLU B 202 REMARK 465 SER B 203 REMARK 465 ARG B 204 REMARK 465 LYS B 205 REMARK 465 GLY B 206 REMARK 465 GLN B 207 REMARK 465 GLU B 208 REMARK 465 ARG B 209 REMARK 465 LEU B 210 REMARK 465 GLU B 211 REMARK 465 HIS B 212 REMARK 465 HIS B 213 REMARK 465 HIS B 214 REMARK 465 HIS B 215 REMARK 465 HIS B 216 REMARK 465 HIS B 217 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 MET A 159 60.70 -119.90 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A 547 DISTANCE = 9.18 ANGSTROMS REMARK 525 HOH B 559 DISTANCE = 6.05 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue RQ7 A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue RQ7 B 301 DBREF 6VWC A 1 25 UNP Q07817 B2CL1_HUMAN 1 25 DBREF 6VWC A 83 209 UNP Q07817 B2CL1_HUMAN 83 209 DBREF 6VWC B 1 75 UNP Q07817 B2CL1_HUMAN 1 25 DBREF 6VWC B 83 209 UNP Q07817 B2CL1_HUMAN 83 209 SEQADV 6VWC ALA A 24 UNP Q07817 TRP 24 ENGINEERED MUTATION SEQADV 6VWC GLY A 76 UNP Q07817 LINKER SEQADV 6VWC GLY A 77 UNP Q07817 LINKER SEQADV 6VWC GLY A 78 UNP Q07817 LINKER SEQADV 6VWC GLY A 79 UNP Q07817 LINKER SEQADV 6VWC GLY A 80 UNP Q07817 LINKER SEQADV 6VWC GLY A 81 UNP Q07817 LINKER SEQADV 6VWC GLY A 82 UNP Q07817 LINKER SEQADV 6VWC LYS A 158 UNP Q07817 GLU 158 ENGINEERED MUTATION SEQADV 6VWC ALA A 189 UNP Q07817 ASP 189 ENGINEERED MUTATION SEQADV 6VWC LEU A 210 UNP Q07817 EXPRESSION TAG SEQADV 6VWC GLU A 211 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS A 212 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS A 213 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS A 214 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS A 215 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS A 216 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS A 217 UNP Q07817 EXPRESSION TAG SEQADV 6VWC ALA B 24 UNP Q07817 TRP 24 ENGINEERED MUTATION SEQADV 6VWC GLY B 76 UNP Q07817 LINKER SEQADV 6VWC GLY B 77 UNP Q07817 LINKER SEQADV 6VWC GLY B 78 UNP Q07817 LINKER SEQADV 6VWC GLY B 79 UNP Q07817 LINKER SEQADV 6VWC GLY B 80 UNP Q07817 LINKER SEQADV 6VWC GLY B 81 UNP Q07817 LINKER SEQADV 6VWC GLY B 82 UNP Q07817 LINKER SEQADV 6VWC LYS B 158 UNP Q07817 GLU 158 ENGINEERED MUTATION SEQADV 6VWC ALA B 189 UNP Q07817 ASP 189 ENGINEERED MUTATION SEQADV 6VWC LEU B 210 UNP Q07817 EXPRESSION TAG SEQADV 6VWC GLU B 211 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS B 212 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS B 213 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS B 214 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS B 215 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS B 216 UNP Q07817 EXPRESSION TAG SEQADV 6VWC HIS B 217 UNP Q07817 EXPRESSION TAG SEQRES 1 A 167 MET SER GLN SER ASN ARG GLU LEU VAL VAL ASP PHE LEU SEQRES 2 A 167 SER TYR LYS LEU SER GLN LYS GLY TYR SER ALA SER GLY SEQRES 3 A 167 GLY GLY GLY GLY GLY GLY MET ALA ALA VAL LYS GLN ALA SEQRES 4 A 167 LEU ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG SEQRES 5 A 167 ARG ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR SEQRES 6 A 167 PRO GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN SEQRES 7 A 167 GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL SEQRES 8 A 167 ALA PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER SEQRES 9 A 167 VAL ASP LYS LYS MET GLN VAL LEU VAL SER ARG ILE ALA SEQRES 10 A 167 ALA TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO SEQRES 11 A 167 TRP ILE GLN GLU ASN GLY GLY TRP ALA THR PHE VAL GLU SEQRES 12 A 167 LEU TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY SEQRES 13 A 167 GLN GLU ARG LEU GLU HIS HIS HIS HIS HIS HIS SEQRES 1 B 167 MET SER GLN SER ASN ARG GLU LEU VAL VAL ASP PHE LEU SEQRES 2 B 167 SER TYR LYS LEU SER GLN LYS GLY TYR SER ALA SER GLY SEQRES 3 B 167 GLY GLY GLY GLY GLY GLY MET ALA ALA VAL LYS GLN ALA SEQRES 4 B 167 LEU ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG SEQRES 5 B 167 ARG ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR SEQRES 6 B 167 PRO GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN SEQRES 7 B 167 GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL SEQRES 8 B 167 ALA PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER SEQRES 9 B 167 VAL ASP LYS LYS MET GLN VAL LEU VAL SER ARG ILE ALA SEQRES 10 B 167 ALA TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO SEQRES 11 B 167 TRP ILE GLN GLU ASN GLY GLY TRP ALA THR PHE VAL GLU SEQRES 12 B 167 LEU TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY SEQRES 13 B 167 GLN GLU ARG LEU GLU HIS HIS HIS HIS HIS HIS HET RQ7 A 301 43 HET RQ7 B 301 43 HETNAM RQ7 6-{8-[(1,3-BENZOTHIAZOL-2-YL)CARBAMOYL]-3,4- HETNAM 2 RQ7 DIHYDROISOQUINOLIN-2(1H)-YL}-3-{1-[(PYRIDIN-4-YL) HETNAM 3 RQ7 METHYL]-1H-PYRAZOL-4-YL}PYRIDINE-2-CARBOXYLIC ACID FORMUL 3 RQ7 2(C32 H25 N7 O3 S) FORMUL 5 HOH *306(H2 O) HELIX 1 AA1 SER A 2 LYS A 20 1 19 HELIX 2 AA2 MET A 83 TYR A 101 1 19 HELIX 3 AA3 ARG A 102 PHE A 105 5 4 HELIX 4 AA4 ASP A 107 LEU A 112 5 6 HELIX 5 AA5 ALA A 119 PHE A 131 1 13 HELIX 6 AA6 ASN A 136 LYS A 157 1 22 HELIX 7 AA7 GLN A 160 LEU A 178 1 19 HELIX 8 AA8 LEU A 178 ASN A 185 1 8 HELIX 9 AA9 GLY A 186 GLY A 196 1 11 HELIX 10 AB1 GLN B 3 LYS B 20 1 18 HELIX 11 AB2 MET B 83 TYR B 101 1 19 HELIX 12 AB3 ARG B 102 PHE B 105 5 4 HELIX 13 AB4 ASP B 107 GLN B 111 5 5 HELIX 14 AB5 ALA B 119 PHE B 131 1 13 HELIX 15 AB6 ASN B 136 LYS B 157 1 22 HELIX 16 AB7 GLN B 160 LEU B 178 1 19 HELIX 17 AB8 LEU B 178 ASN B 185 1 8 HELIX 18 AB9 GLY B 186 GLY B 196 1 11 SITE 1 AC1 22 SER A 25 ALA A 93 PHE A 97 ARG A 102 SITE 2 AC1 22 PHE A 105 SER A 106 ASP A 107 LEU A 108 SITE 3 AC1 22 GLU A 129 LEU A 130 ARG A 132 ASN A 136 SITE 4 AC1 22 GLY A 138 ARG A 139 VAL A 141 ALA A 142 SITE 5 AC1 22 SER A 145 PHE A 146 ALA A 149 TYR A 195 SITE 6 AC1 22 HOH A 465 HOH A 492 SITE 1 AC2 23 ALA B 93 PHE B 97 ARG B 102 PHE B 105 SITE 2 AC2 23 SER B 106 ASP B 107 LEU B 108 GLU B 129 SITE 3 AC2 23 LEU B 130 ARG B 132 ASN B 136 GLY B 138 SITE 4 AC2 23 ARG B 139 VAL B 141 ALA B 142 SER B 145 SITE 5 AC2 23 PHE B 146 ALA B 149 TYR B 195 HOH B 419 SITE 6 AC2 23 HOH B 423 HOH B 457 HOH B 498 CRYST1 33.304 94.584 54.272 90.00 90.93 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.030026 0.000000 0.000487 0.00000 SCALE2 0.000000 0.010573 0.000000 0.00000 SCALE3 0.000000 0.000000 0.018428 0.00000